After RBC Capital and Needham gave Pacira Pharmaceuticals (NASDAQ: PCRX) a Buy rating last month, the company received another Buy, this time from Wedbush. Analyst Liana Moussatos reiterated a Buy rating on Pacira Pharmaceuticals today and set a price target of $94.00. The company’s shares closed last Thursday at $52.90.
According to TipRanks.com, Moussatos is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -13.0% and a 29.9% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Aquestive Therapeutics, and Liquidia Technologies.
Currently, the analyst consensus on Pacira Pharmaceuticals is a Strong Buy with an average price target of $86.20, implying a 62.0% upside from current levels. In a report issued on July 7, RBC Capital also maintained a Buy rating on the stock with a $83.00 price target.
Pacira Pharmaceuticals’ market cap is currently $2.45B and has a P/E ratio of 64.31.
Based on the recent corporate insider activity of 68 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PCRX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pacira Biosciences, Inc. develops and manufactures injectable therapeutic products. The firm engages in the development, commercialization and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ.
Read More on PCRX: